Finance

Beta
Lists
RMD:NYSE
Resmed Inc
$198.60
+1.07%
(+2.10) 1D
Jun 25, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RMD...
Open
$199.24
High
$202.68
Low
$198.25
Mkt. cap
28.81B
Avg. vol.
1.53M
Volume
1.10M
Dividend
1.21%
Quarterly dividend
$0.60
Ex-dividend date
May 14, 2026
P/E ratio
19.15
52-wk high
$293.81
52-wk low
$180.26
EPS
$10.37
Beta
0.80
Shares outstanding
145.06M
No. of employees
11K
Open
$199.24
High
$202.68
Low
$198.25
Mkt. cap
28.81B
Avg. vol.
1.53M
Volume
1.10M
Dividend
1.21%
Quarterly dividend
$0.60
Ex-dividend date
May 14, 2026
P/E ratio
19.15
52-wk high
$293.81
52-wk low
$180.26
EPS
$10.37
Beta
0.80
Shares outstanding
145.06M
No. of employees
11K
News stories
From sources across the web
Profile
ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19. Resmed also provides software to out-of-hospital care agencies to streamline transitions of care into and between these care settings for seniors and their care providers. Resmed employs more than 8,000 people worldwide as of June 2022. The company operates in more than 140 countries worldwide, and has manufacturing facilities in Australia, Singapore, France, and the United States. Revenue was US$4.7 billion in fiscal year 2024. Wikipedia
About Resmed Inc
CEOMichael J. Farrell
Employees10.6K
FoundedJun 1989
HeadquartersSan Diego, California, United States
SectorMedical device
Websiteresmed.com
Analyst ratings
Based on 14 analysts giving stock ratings to RMD in the past 3 months
Buy
Buy
8
Hold
6
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for RMD in the last 3 months.
Highest
Current $198.60
$321.00 (+61.63%)
Average
$256.09 (+28.95%)
Lowest
$225.00 (+13.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Vazquez
William Blair
Buy
Maintained
-
-
06/22/2026
Brett Fishbin
KeyBanc
Buy
Reiterated
$266.00
+33.9%
06/22/2026
David Bailey
Morgan Stanley
Hold
Downgraded
$230.00
+15.8%
06/17/2026
Laura Sutcliffe
Citi
Buy
Reiterated
$270.00
+36%
06/15/2026
Lyanne Harrison
Bank of America Securities
Buy
Reiterated
$320.00
+61.1%
06/04/2026
Nathan Treybeck
Wells Fargo
Hold
Reiterated
$227.00
+14.3%
05/29/2026
Michael Matson
Needham
Hold
Maintained
-
-
05/15/2026
Adam Maeder
Piper Sandler
Hold
Maintained
$233.00
+17.3%
05/06/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$235.00
+18.3%
05/04/2026
David Rescott
Robert W. Baird
Hold
Maintained
$225.00
+13.3%
05/01/2026
Craig Wong-Pan
RBC Capital
Buy
Maintained
$321.00
+61.6%
05/01/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$227.00
+14.3%
05/01/2026
Jonathan Block
Stifel Nicolaus
Hold
Maintained
$235.00
+18.3%
05/01/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
-
-
04/15/2026
Chris Cooper
J.P. Morgan
Buy
Initiated
-
-
04/15/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$255.00
+28.4%
04/13/2026
Larry Biegelsen
Wells Fargo
Hold
Maintained
$270.00
+36%
01/30/2026
Mark Wilson CFA
RBC Capital
Buy
Maintained
$314.00
+58.1%
01/30/2026
Last report
Apr 30, 2026
Fiscal period
Q3 2026
EPS / Est. (USD)
$0.29 / $2.80
-89.79%miss
Revenue / Est. (USD)
1.43B / 1.42B
+0.63%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.35B
1.34B
1.42B
1.43B
Cost of goods sold
518.56M
506.94M
536.28M
532.58M
Cost of revenue
518.56M
506.94M
536.28M
532.58M
Research and development expenses
86.44M
87.32M
90.97M
94.27M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
265.12M
259.19M
275.70M
279.80M
Operating expense
372.86M
366.29M
386.24M
393.16M
Total operating expenses
891.42M
873.24M
922.51M
925.74M
Operating income
456.57M
462.35M
500.30M
505.67M
Other non operating income
-36.00K
-3.84M
42.00K
181.00K
EBT including unusual items
458.05M
446.79M
496.15M
502.31M
EBT excluding unusual items
462.62M
468.79M
504.48M
518.30M
Income tax expense
78.35M
98.26M
103.56M
103.58M
Effective tax rate
17.10%
21.99%
20.87%
20.62%
Other operating expenses
-
-
-
-
Net income
379.70M
348.54M
392.59M
398.73M
Net profit margin
28.17%
26.10%
27.59%
27.86%
Earnings per share
2.55
2.55
2.81
0.29
Interest and investment income
9.57M
4.69M
4.46M
3.80M
Interest expense
-
-
-
-
Net interest expenses
9.57M
4.69M
4.46M
3.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
513.86M
503.64M
543.79M
558.22M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of RMD
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer